{"id":15317,"date":"2024-12-03T16:55:45","date_gmt":"2024-12-03T16:55:45","guid":{"rendered":"https:\/\/www.wistar.org\/?p=15317"},"modified":"2024-12-03T17:06:59","modified_gmt":"2024-12-03T17:06:59","slug":"wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer","status":"publish","type":"post","link":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/","title":{"rendered":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer"},"content":{"rendered":"<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2024\/03\/blue_box_logo-Converted.png\" alt=\"\"><\/p>\n<div>PRESS RELEASE<\/div>\n<ul>\n<li>\n<div>\n<p style=\"text-align: right;\"><strong>CONTACT:<\/strong><\/p>\n<\/div>\n<\/li>\n<li>\n<div>\n<p style=\"text-align: right;\">Darien Sutton<\/p>\n<\/div>\n<\/li>\n<li>\n<div>\n<p style=\"text-align: right;\"><a href=\"tel:215-898-3988\">215-898-3988<\/a>\u00a0 |\u00a0 <a href=\"mailto:dsutton@wistar.org\">dsutton@wistar.org<\/a><\/p>\n<\/div>\n<\/li>\n<\/ul>\n<div><em>Trispecific Design Controls Glioblastoma Tumors in Preclinical Models<\/em><\/div>\n<div>\n<p><strong>PHILADELPHIA \u2014 (December 3rd, 2024) \u2014<\/strong> The Wistar Institute\u2019s <a href=\"https:\/\/www.wistar.org\/our-scientists\/david-weiner\/\"><strong>David B. Weiner, Ph.D.<\/strong><\/a> \u2014 Executive Vice President, director of the Vaccine &amp; Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research \u2014 and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma. Their findings were published in the paper, <a href=\"https:\/\/jitc.bmj.com\/content\/12\/12\/e009604\" target=\"_blank\" rel=\"noopener\">\u201cNovel tri-specific T-cell engager targeting IL-13R\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells,\u201d<\/a> in the <em>Journal for ImmunoTherapy of Cancer.<\/em><\/p>\n<\/p>\n<p>\u201cThis study utilizes a novel design to build a glioblastoma-targeting \u2018trispecific\u2019 antibody deployed against a laboratory model of glioblastoma, which has the potential to be made entirely in patients as a glioblastoma therapy in the future,\u201d said corresponding author, Dr. David Weiner. \u201cWe\u2019re hopeful that this will have future applications for preventing tumor escape mechanisms that block response to therapy in a variety of cancers.\u201d<\/p>\n<\/p>\n<p>Glioblastoma is the deadliest form of brain cancer, with less than a 5% five-year survival rate. One of the key contributors to glioblastoma\u2019s poor outlook is its natural immunosuppression coupled with its intrinsic diversity \u2014 a one-two punch that limits immune successes against controlling glioblastoma in patients.<\/p>\n<\/p>\n<p>All cancers \u2014 particularly immune-silent, fast-growing cancers like glioblastoma \u2014 produce signals called antigens that scientists can use in immune therapies to manually alert the immune system to the presence of incognito cancers. But designing an effective immune therapy for glioblastoma is especially challenging because glioblastoma antigens can vary greatly. That variability means that any effective immune therapy would need to deliver a large amount of information to the immune system.<\/p>\n<\/p>\n<p>The team designed a unique trispecific antibody encoded in a DNA-encoded delivery mechanism. Their DNA-encoded trispecifics, named \u201cDTriTEs,\u201d linked cancer-killing T cells through the CD3 protein with two different glioblastoma antigens: the IL-13R\u03b12 protein and the EGFRvIII protein. This allows the immune system\u2019s T cells to be alerted and activated when they encounter diverse glioblastoma tumors expressing either or both of these antigens.\u00a0<\/p>\n<\/p>\n<p>In pre-clinical laboratory testing, one DTriTE design stood out for its anticancer potency. Not only did the design produce robust activation of anti-cancer killer T cells, but it also engaged another type of tumor-clearing cell, the Natural Killer (NK) T cells. The DTriTE design was the most potent treatment that provided sustained survival and tumor control in 100% of the glioblastoma challenge models for the duration of the study. In a long-term challenge model meant to evaluate the DTriTE\u2019s ability to sustain anti-cancer efficacy over a longer period of time, 66% of the models treated with the DTriTE showed lasting tumor suppression and survival, which no other comparison treatment achieved.<\/p>\n<\/p>\n<p>\u201cBased on this early-stage testing, our data show that, even for a cancer as resistant to treatment as heterogenous glioblastoma, the novel DTriTE design can induce a potent and lasting anticancer response, potentially adding a new tool to our arsenal of approaches,\u201d said the paper\u2019s first author and Weiner lab Ph.D. student, Daniel H. Park. \u201cWe\u2019re excited to continue to expand on these designs for potential treatment of glioblastoma and, in the future, for other types of cancer that haven\u2019t responded to immunotherapy due to similar immune issues.\u201d<\/p>\n<\/p>\n<p><strong>Co-authors: <\/strong>Daniel H. Park,<sup>1,2<\/sup> Pratik S. Bhojnagarwala,<sup>1<\/sup> Kevin Liaw,<sup>1<\/sup> Devivasha Bordoloi,<sup>1<\/sup> Nicholas J. Tursi,<sup>1,2<\/sup> Shushu Zhao,<sup>1<\/sup> Zev A Binder,<sup>2,3<\/sup> Donald O\u2019Rourke,<sup>2,3<\/sup> and David B. Weiner<sup>1,2<\/sup><\/p>\n<p><sup>1 <\/sup>The Wistar Institute<\/p>\n<p><sup>2 <\/sup>The Perelman School of Medicine at the University of Pennsylvania<\/p>\n<p><sup>3 <\/sup>GBM Translational Center of Excellence at the Abramson Cancer Center<\/p>\n<p><strong>Work supported by:<\/strong> This research was funded by a sponsored research agreement from Inovio Pharmaceuticals. Dr. David B. Weiner is supported by the W.W. Smith Charitable Trust Professorship in Cancer Research, which covered aspects of the work.<\/p>\n<p><strong>Publication information<\/strong>: \u201cNovel tri-specific T-cell engager targeting IL-13R\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells,\u201d from <em>Journal for ImmunoTherapy of Cancer<\/em><\/p>\n<\/div>\n<div>\n<p style=\"text-align: center;\"><em><strong>For a printer-friendly version of this release, please click <a href=\"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-Glio-Release_12.3.pdf\" target=\"_blank\" rel=\"noopener\">here<\/a>.<\/strong><\/em><\/p>\n<\/div>\n<div>\n<h3>ABOUT THE WISTAR INSTITUTE:<\/h3>\n<div>\n<p><span>The Wistar Institute is the nation\u2019s first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world\u2019s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers<\/span>. <a href=\"\/\">wistar.org<\/a><\/p>\n<\/div>\n<\/div>\n<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2023\/05\/footer-company-logo.jpg\" alt=\"\"><\/p>\n<hr>\n<p><!--more--><br \/>\n<!-- {\"type\":\"layout\",\"children\":[{\"type\":\"section\",\"props\":{\"image_position\":\"center-center\",\"padding\":\"xsmall\",\"style\":\"default\",\"title_breakpoint\":\"xl\",\"title_position\":\"top-left\",\"title_rotation\":\"left\",\"vertical_align\":\"\",\"width\":\"\"},\"children\":[{\"type\":\"row\",\"props\":{\"column_gap\":\"collapse\",\"layout\":\"1-2,1-2\",\"margin\":\"small\",\"row_gap\":\"collapse\",\"width\":\"small\"},\"children\":[{\"type\":\"column\",\"props\":{\"image\":\"#\",\"image_position\":\"center-center\",\"media_background\":\"#D6E2EC\",\"padding\":\"xsmall\",\"position_sticky_breakpoint\":\"m\",\"style\":\"tile-secondary\",\"vertical_align\":\"middle\",\"width_large\":\"1-2\"},\"children\":[{\"type\":\"image\",\"props\":{\"animation\":\"none\",\"image\":\"wp-content\\\/uploads\\\/2024\\\/03\\\/blue_box_logo-Converted.png\",\"image_svg_color\":\"emphasis\",\"image_width\":277,\"margin\":\"medium\",\"parallax_breakpoint\":\"l\",\"parallax_easing\":\"1\",\"parallax_x\":\"150,0\",\"text_align\":\"left\"}}]},{\"type\":\"column\",\"props\":{\"image\":\"#\",\"image_position\":\"center-center\",\"media_background\":\"#D6E2EC\",\"padding\":\"xsmall\",\"position_sticky_breakpoint\":\"m\",\"style\":\"tile-secondary\",\"text_color\":\"dark\",\"vertical_align\":\"middle\",\"width_large\":\"1-2\"},\"children\":[{\"type\":\"headline\",\"props\":{\"content\":\"PRESS RELEASE\",\"text_align\":\"right\",\"title_color\":\"success\",\"title_element\":\"div\",\"title_style\":\"h1\"}},{\"type\":\"list\",\"props\":{\"column_breakpoint\":\"m\",\"image_align\":\"left\",\"image_svg_color\":\"emphasis\",\"image_vertical_align\":true,\"list_element\":\"ul\",\"list_horizontal_separator\":\", \",\"list_size\":\"collapse\",\"list_type\":\"vertical\",\"show_image\":true,\"show_link\":true},\"children\":[{\"type\":\"list_item\",\"props\":{\"content\":\"\n\n<p style=\\\"text-align: right;\\\"><strong>CONTACT:<\\\/strong><\\\/p>\"}},{\"type\":\"list_item\",\"props\":{\"content\":\"\n\n<p style=\\\"text-align: right;\\\">Darien Sutton<\\\/p>\"}},{\"type\":\"list_item\",\"props\":{\"content\":\"\n\n<p style=\\\"text-align: right;\\\"><a href=\\\"tel:215-898-3988\\\">215-898-3988<\\\/a>\\u00a0 |\\u00a0 <a href=\\\"mailto:dsutton@wistar.org\\\">dsutton@wistar.org<\\\/a><\\\/p>\"}}]}]}]},{\"type\":\"row\",\"props\":{\"margin\":\"default\",\"width\":\"small\"},\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\"},\"children\":[{\"type\":\"headline\",\"props\":{\"text_align\":\"center\",\"title_color\":\"emphasis\",\"title_element\":\"h1\",\"title_style\":\"h4\"},\"source\":{\"query\":{\"name\":\"posts.singlePost\"},\"props\":{\"content\":{\"filters\":{\"search\":\"\"},\"name\":\"title\"}}}},{\"type\":\"headline\",\"props\":{\"content\":\"<em>Trispecific Design Controls Glioblastoma Tumors in Preclinical Models<\\\/em>\",\"text_align\":\"center\",\"title_element\":\"div\",\"title_style\":\"h5\"}},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<p><strong>PHILADELPHIA \\u2014 (December 3rd, 2024) \\u2014<\\\/strong> The Wistar Institute\\u2019s <a href=\\\"https:\\\/\\\/www.wistar.org\\\/our-scientists\\\/david-weiner\\\/\\\"><strong>David B. Weiner, Ph.D.<\\\/strong><\\\/a> \\u2014 Executive Vice President, director of the Vaccine &amp; Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research \\u2014 and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma. Their findings were published in the paper, <a href=\\\"https:\\\/\\\/jitc.bmj.com\\\/content\\\/12\\\/12\\\/e009604\\\" target=\\\"_blank\\\" rel=\\\"noopener\\\">\\u201cNovel tri-specific T-cell engager targeting IL-13R\\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells,\\u201d<\\\/a> in the <em>Journal for ImmunoTherapy of Cancer.<\\\/em><\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>\\u201cThis study utilizes a novel design to build a glioblastoma-targeting \\u2018trispecific\\u2019 antibody deployed against a laboratory model of glioblastoma, which has the potential to be made entirely in patients as a glioblastoma therapy in the future,\\u201d said corresponding author, Dr. David Weiner. \\u201cWe\\u2019re hopeful that this will have future applications for preventing tumor escape mechanisms that block response to therapy in a variety of cancers.\\u201d<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>Glioblastoma is the deadliest form of brain cancer, with less than a 5% five-year survival rate. One of the key contributors to glioblastoma\\u2019s poor outlook is its natural immunosuppression coupled with its intrinsic diversity \\u2014 a one-two punch that limits immune successes against controlling glioblastoma in patients.<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>All cancers \\u2014 particularly immune-silent, fast-growing cancers like glioblastoma \\u2014 produce signals called antigens that scientists can use in immune therapies to manually alert the immune system to the presence of incognito cancers. But designing an effective immune therapy for glioblastoma is especially challenging because glioblastoma antigens can vary greatly. That variability means that any effective immune therapy would need to deliver a large amount of information to the immune system.<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>The team designed a unique trispecific antibody encoded in a DNA-encoded delivery mechanism. Their DNA-encoded trispecifics, named \\u201cDTriTEs,\\u201d linked cancer-killing T cells through the CD3 protein with two different glioblastoma antigens: the IL-13R\\u03b12 protein and the EGFRvIII protein. This allows the immune system\\u2019s T cells to be alerted and activated when they encounter diverse glioblastoma tumors expressing either or both of these antigens.\\u00a0<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>In pre-clinical laboratory testing, one DTriTE design stood out for its anticancer potency. Not only did the design produce robust activation of anti-cancer killer T cells, but it also engaged another type of tumor-clearing cell, the Natural Killer (NK) T cells. The DTriTE design was the most potent treatment that provided sustained survival and tumor control in 100% of the glioblastoma challenge models for the duration of the study. In a long-term challenge model meant to evaluate the DTriTE\\u2019s ability to sustain anti-cancer efficacy over a longer period of time, 66% of the models treated with the DTriTE showed lasting tumor suppression and survival, which no other comparison treatment achieved.<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p>\\u201cBased on this early-stage testing, our data show that, even for a cancer as resistant to treatment as heterogenous glioblastoma, the novel DTriTE design can induce a potent and lasting anticancer response, potentially adding a new tool to our arsenal of approaches,\\u201d said the paper\\u2019s first author and Weiner lab Ph.D. student, Daniel H. Park. \\u201cWe\\u2019re excited to continue to expand on these designs for potential treatment of glioblastoma and, in the future, for other types of cancer that haven\\u2019t responded to immunotherapy due to similar immune issues.\\u201d<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p><strong>Co-authors: <\\\/strong>Daniel H. Park,<sup>1,2<\\\/sup> Pratik S. Bhojnagarwala,<sup>1<\\\/sup> Kevin Liaw,<sup>1<\\\/sup> Devivasha Bordoloi,<sup>1<\\\/sup> Nicholas J. Tursi,<sup>1,2<\\\/sup> Shushu Zhao,<sup>1<\\\/sup> Zev A Binder,<sup>2,3<\\\/sup> Donald O\\u2019Rourke,<sup>2,3<\\\/sup> and David B. Weiner<sup>1,2<\\\/sup><\\\/p>\\n\n\n<p><sup>1 <\\\/sup>The Wistar Institute<\\\/p>\\n\n\n<p><sup>2 <\\\/sup>The Perelman School of Medicine at the University of Pennsylvania<\\\/p>\\n\n\n<p><sup>3 <\\\/sup>GBM Translational Center of Excellence at the Abramson Cancer Center<\\\/p>\\n\n\n<p><strong>Work supported by:<\\\/strong> This research was funded by a sponsored research agreement from Inovio Pharmaceuticals. Dr. David B. Weiner is supported by the W.W. Smith Charitable Trust Professorship in Cancer Research, which covered aspects of the work.<\\\/p>\\n\n\n<p><strong>Publication information<\\\/strong>: \\u201cNovel tri-specific T-cell engager targeting IL-13R\\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells,\\u201d from <em>Journal for ImmunoTherapy of Cancer<\\\/em><\\\/p>\",\"margin\":\"default\"}},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<p style=\\\"text-align: center;\\\"><em><strong>For a printer-friendly version of this release, please click <a href=\\\"https:\\\/\\\/www.wistar.org\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/Weiner-Glio-Release_12.3.pdf\\\" target=\\\"_blank\\\" rel=\\\"noopener\\\">here<\\\/a>.<\\\/strong><\\\/em><\\\/p>\",\"margin\":\"default\"}},{\"type\":\"panel\",\"props\":{\"content\":\"\n\n<p><span>The Wistar Institute is the nation\\u2019s first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world\\u2019s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers<\\\/span>. <a href=\\\"\\\/\\\">wistar.org<\\\/a><\\\/p>\",\"content_column_breakpoint\":\"m\",\"icon_width\":80,\"image_align\":\"top\",\"image_grid_breakpoint\":\"m\",\"image_grid_width\":\"1-2\",\"image_svg_color\":\"emphasis\",\"link_style\":\"default\",\"link_text\":\"Read more\",\"margin\":\"medium\",\"meta_align\":\"below-title\",\"meta_element\":\"div\",\"meta_style\":\"text-meta\",\"panel_padding\":\"small\",\"panel_style\":\"card-default\",\"title\":\"ABOUT THE WISTAR INSTITUTE:\",\"title_align\":\"top\",\"title_element\":\"h3\",\"title_grid_breakpoint\":\"m\",\"title_grid_width\":\"1-2\",\"title_hover_style\":\"reset\"}}]}]},{\"type\":\"row\",\"props\":{\"divider\":false,\"layout\":\"1-4,1-2,1-4\",\"width\":\"small\"},\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\",\"vertical_align\":\"bottom\",\"width_medium\":\"1-4\"}},{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\",\"vertical_align\":\"middle\",\"width_medium\":\"1-2\"},\"children\":[{\"type\":\"image\",\"props\":{\"animation\":\"none\",\"image\":\"wp-content\\\/uploads\\\/2023\\\/05\\\/footer-company-logo.jpg\",\"image_height\":100,\"image_svg_color\":\"emphasis\",\"margin\":\"default\",\"parallax_breakpoint\":\"l\",\"parallax_easing\":\"1\",\"parallax_x\":\"150,0\",\"text_align\":\"center\"}}]},{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\",\"width_medium\":\"1-4\"}}]}],\"name\":\"Post\"},{\"type\":\"section\",\"props\":{\"image_position\":\"center-center\",\"padding_remove_bottom\":true,\"style\":\"default\",\"title_breakpoint\":\"xl\",\"title_position\":\"top-left\",\"title_rotation\":\"left\",\"vertical_align\":\"\",\"width\":\"default\"},\"children\":[{\"type\":\"row\",\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\"},\"children\":[{\"type\":\"divider\",\"props\":{\"divider_element\":\"hr\"}}]}]}],\"name\":\"Hero\"}],\"version\":\"4.4.16\"} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA \u2014 (December 3rd, 2024) \u2014 The Wistar Institute\u2019s David B. Weiner, Ph.D. \u2014 Executive Vice President, director of the Vaccine &#038; Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research \u2014 and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma. Their findings were published in the paper, \u201cNovel tri-specific T-cell engager targeting IL-13R\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells,\u201d in the Journal for ImmunoTherapy of Cancer.<\/p>\n","protected":false},"author":3,"featured_media":15330,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[105],"class_list":["post-15317","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases","tag-weiner"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.5 (Yoast SEO v24.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer - The Wistar Institute<\/title>\n<meta name=\"description\" content=\"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer Press Releases\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer\" \/>\n<meta property=\"og:description\" content=\"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer Press Releases\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"The Wistar Institute\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/thewistarinstitute\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T16:55:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T17:06:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"The Wistar Institute\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TheWistar\" \/>\n<meta name=\"twitter:site\" content=\"@TheWistar\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"The Wistar Institute\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/\"},\"author\":{\"name\":\"The Wistar Institute\",\"@id\":\"https:\/\/www.wistar.org\/#\/schema\/person\/3b0901f5f309823d3b7f5adc553b4b11\"},\"headline\":\"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer\",\"datePublished\":\"2024-12-03T16:55:45+00:00\",\"dateModified\":\"2024-12-03T17:06:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/\"},\"wordCount\":793,\"publisher\":{\"@id\":\"https:\/\/www.wistar.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png\",\"keywords\":[\"Weiner\"],\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/\",\"url\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/\",\"name\":\"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer - The Wistar Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.wistar.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png\",\"datePublished\":\"2024-12-03T16:55:45+00:00\",\"dateModified\":\"2024-12-03T17:06:59+00:00\",\"description\":\"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer Press Releases\",\"breadcrumb\":{\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#primaryimage\",\"url\":\"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png\",\"contentUrl\":\"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png\",\"width\":900,\"height\":450},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.wistar.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.wistar.org\/#website\",\"url\":\"https:\/\/www.wistar.org\/\",\"name\":\"www.wistar.org\",\"description\":\"A Global Leader in Biomedical Research\",\"publisher\":{\"@id\":\"https:\/\/www.wistar.org\/#organization\"},\"alternateName\":\"wistar.org\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.wistar.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.wistar.org\/#organization\",\"name\":\"The Wistar Institute\",\"url\":\"https:\/\/www.wistar.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.wistar.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.wistar.org\/wp-content\/uploads\/2023\/09\/wistar_logoFINAL.jpg\",\"contentUrl\":\"https:\/\/www.wistar.org\/wp-content\/uploads\/2023\/09\/wistar_logoFINAL.jpg\",\"width\":300,\"height\":150,\"caption\":\"The Wistar Institute\"},\"image\":{\"@id\":\"https:\/\/www.wistar.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/thewistarinstitute\",\"https:\/\/x.com\/TheWistar\",\"https:\/\/www.linkedin.com\/company\/the-wistar-institute\",\"https:\/\/www.youtube.com\/user\/TheWistarInstitute\",\"https:\/\/www.instagram.com\/thewistar\/\"],\"description\":\"The Wistar Institute is a global leader in biomedical research with special expertise in cancer, immunology, infectious disease, and vaccine development. Wistar is the nation\u2019s first independent institution devoted to biomedical research, training the next generation of leaders in science and supporting the innovation ecosystem.\",\"email\":\"comm-marketing@wistar.org\",\"telephone\":\"215-898-3988\",\"legalName\":\"The Wistar Institute\",\"foundingDate\":\"1892-01-01\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"201\",\"maxValue\":\"500\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.wistar.org\/#\/schema\/person\/3b0901f5f309823d3b7f5adc553b4b11\",\"name\":\"The Wistar Institute\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.wistar.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2f735fa5a3993de828b09060351d9aff?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2f735fa5a3993de828b09060351d9aff?s=96&d=mm&r=g\",\"caption\":\"The Wistar Institute\"},\"url\":\"https:\/\/www.wistar.org\/author\/hannah\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer - The Wistar Institute","description":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer Press Releases","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer","og_description":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer Press Releases","og_url":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/","og_site_name":"The Wistar Institute","article_publisher":"https:\/\/www.facebook.com\/thewistarinstitute","article_published_time":"2024-12-03T16:55:45+00:00","article_modified_time":"2024-12-03T17:06:59+00:00","og_image":[{"width":900,"height":450,"url":"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png","type":"image\/png"}],"author":"The Wistar Institute","twitter_card":"summary_large_image","twitter_creator":"@TheWistar","twitter_site":"@TheWistar","twitter_misc":{"Written by":"The Wistar Institute","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#article","isPartOf":{"@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/"},"author":{"name":"The Wistar Institute","@id":"https:\/\/www.wistar.org\/#\/schema\/person\/3b0901f5f309823d3b7f5adc553b4b11"},"headline":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer","datePublished":"2024-12-03T16:55:45+00:00","dateModified":"2024-12-03T17:06:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/"},"wordCount":793,"publisher":{"@id":"https:\/\/www.wistar.org\/#organization"},"image":{"@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png","keywords":["Weiner"],"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/","url":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/","name":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer - The Wistar Institute","isPartOf":{"@id":"https:\/\/www.wistar.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png","datePublished":"2024-12-03T16:55:45+00:00","dateModified":"2024-12-03T17:06:59+00:00","description":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer Press Releases","breadcrumb":{"@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#primaryimage","url":"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png","contentUrl":"https:\/\/www.wistar.org\/wp-content\/uploads\/2024\/12\/Weiner-PR-banner.png","width":900,"height":450},{"@type":"BreadcrumbList","@id":"https:\/\/www.wistar.org\/press-releases\/wistar-institute-researchers-design-novel-immunotherapy-for-brain-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.wistar.org\/"},{"@type":"ListItem","position":2,"name":"Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.wistar.org\/#website","url":"https:\/\/www.wistar.org\/","name":"www.wistar.org","description":"A Global Leader in Biomedical Research","publisher":{"@id":"https:\/\/www.wistar.org\/#organization"},"alternateName":"wistar.org","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.wistar.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.wistar.org\/#organization","name":"The Wistar Institute","url":"https:\/\/www.wistar.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.wistar.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.wistar.org\/wp-content\/uploads\/2023\/09\/wistar_logoFINAL.jpg","contentUrl":"https:\/\/www.wistar.org\/wp-content\/uploads\/2023\/09\/wistar_logoFINAL.jpg","width":300,"height":150,"caption":"The Wistar Institute"},"image":{"@id":"https:\/\/www.wistar.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/thewistarinstitute","https:\/\/x.com\/TheWistar","https:\/\/www.linkedin.com\/company\/the-wistar-institute","https:\/\/www.youtube.com\/user\/TheWistarInstitute","https:\/\/www.instagram.com\/thewistar\/"],"description":"The Wistar Institute is a global leader in biomedical research with special expertise in cancer, immunology, infectious disease, and vaccine development. Wistar is the nation\u2019s first independent institution devoted to biomedical research, training the next generation of leaders in science and supporting the innovation ecosystem.","email":"comm-marketing@wistar.org","telephone":"215-898-3988","legalName":"The Wistar Institute","foundingDate":"1892-01-01","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"201","maxValue":"500"}},{"@type":"Person","@id":"https:\/\/www.wistar.org\/#\/schema\/person\/3b0901f5f309823d3b7f5adc553b4b11","name":"The Wistar Institute","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.wistar.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2f735fa5a3993de828b09060351d9aff?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2f735fa5a3993de828b09060351d9aff?s=96&d=mm&r=g","caption":"The Wistar Institute"},"url":"https:\/\/www.wistar.org\/author\/hannah\/"}]}},"_links":{"self":[{"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/posts\/15317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/comments?post=15317"}],"version-history":[{"count":5,"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/posts\/15317\/revisions"}],"predecessor-version":[{"id":15332,"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/posts\/15317\/revisions\/15332"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/media\/15330"}],"wp:attachment":[{"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/media?parent=15317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/categories?post=15317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wistar.org\/wp-json\/wp\/v2\/tags?post=15317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}